x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:10:29

SF Healthcare Week: Beam's CEO John Evans shares an...

BiotechTV - News ·

2026/01/12

He discusses regulatory feedback the company has received that might allow it to earn an accelerated approval in antitrypsin deficiency. Plus, filing for sickle cell later this year, and how he thinks about new targets.

en-us

00:17:41

SF Healthcare Week: Flagship Pioneering's Founder...

BiotechTV - News ·

2026/01/12

He discusses the theme of his annual letter that was published today, "Choosing Science," and why it is important that our country continues to invest in basic research. Plus, his take on the M&A environment in biotech.

en-us

00:11:11

SF Healthcare Week: Baird Senior Analyst Brian...

BiotechTV - News ·

2026/01/12

He discusses Biohaven, Xenon, Biogen, and Sarepta.

en-us

00:11:08

SF Healthcare Week: Vera Therapeutics’ announced this...

BiotechTV - News ·

2026/01/12

Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.

en-us

00:10:45

SF Healthcare Week: Biohaven's Chairman & CEO Vlad...

BiotechTV - News ·

2026/01/12

He discusses the company's degrader programs, TYK2/JAK1, using myostatin for obesity, and a Kv7 epilepsy program that will have key data this year.

en-us

00:10:59

SF Healthcare Week: Abivax CEO Marc de Garidel...

BiotechTV - News ·

2026/01/12

He discusses the company's accomplishments to date, and highlights learnings about the mechanism and important data in 2026 in the maintenance setting for UC and Crohn's later this year.

en-us

00:32:16

Mizuho Senior Biotech Analyst Salim Syed highlights...

BiotechTV - News ·

2026/01/07

He discusses BridgeBio, Cytokinetics, Vaxcyte, Biogen, and Arcus Biosciences

en-us

00:33:28

William Blair Senior Biotech Analyst Andy Hsieh...

BiotechTV - News ·

2025/12/30

He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026.

en-us

00:45:29

A deep dive discussion on Abivax with Truist Senior...

BiotechTV - News ·

2025/12/29

We discuss the upcoming maintenance data, commercial prospects, Crohn's, and buyout prospects.

en-us

00:20:36

Create Medicines' platform allows it to program CARs...

BiotechTV - News ·

2025/12/12

Co-Founder and CEO Daniel Getts walks us through the platform, which is delivered via LNPs. The lead programs target TROP2, HER2, and GPC3.

en-us

00:13:44

The leaders of London based LabGenius Therapeutics...

BiotechTV - News ·

2025/12/11

CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.

en-us

00:14:56

Bay Area based Medra, which is building a robotics...

BiotechTV - News ·

2025/12/11

Founder and CEO Michelle Lee highlights the key distinction between Medra and other automated lab equipment, which is that Medra's platform is designed to sense and understand its environment and use that knowledge to make its own intelligent decisions.

en-us

00:18:51

Kymera Therapeutics' Founder & CEO Nello Mainolfi...

BiotechTV - News ·

2025/12/10

He talks about Kymera's dosing methodology, and recaps the data from a degredation, biomarker, and clinical outcomes standpoint. Plus, next steps in STAT6, and thoughts on the platform in general and the field more broadly.

en-us

00:19:29

ASH 2025: Kelonia Therapeutics presented convincing...

BiotechTV - News ·

2025/12/09

Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next.

en-us

00:10:22

ASH 2025: MaaT Pharma's microbiome based treatment...

BiotechTV - News ·

2025/12/09

Founder and CEO Hervé Affagard walks us through how this treatment works and highlights the ASH presentation and one year survival data the company has accrued. Plus, how compassionate use is going in the United States.

en-us

00:14:13

ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang...

BiotechTV - News ·

2025/12/09

The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, and update on global studies of the BCR-ABU/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor.

en-us

00:07:51

ASH 2025: Corvus CEO Richard Miller believes that ITK...

BiotechTV - News ·

2025/12/09

He describes the science behind ITK, and goes over ASH data in r/r T-cell lymphoma, where the company is already enrolling a pivotal study. Plus, why the profile of ITK in oncology gives him confidence in its utility for autoimmune disease, and highlighting atopic dermatitis data that will be coming in January.

en-us

00:16:50

ASH 2025: Nurix CEO Arthur Sands discusses his...

BiotechTV - News ·

2025/12/08

He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4.

en-us

00:09:52

ASH 2025: Cullinan Therapeutics CEO Nadim Ahmed...

BiotechTV - News ·

2025/12/08

He describes how this asset binds to the extracellular domain and therefore can work for both wild type patients and those with mutations. Plus, recent regulatory news on zipalertinib and when to expect to see autoimmune data.

en-us

00:13:14

ASH 2025: Kura Oncology CEO Troy Wilson discusses the...

BiotechTV - News ·

2025/12/08

He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion.

en-us

409 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter